Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px
Document › Details

Base4 Innovation Ltd.. (7/8/13). "Press Release: Base4 and Hitachi High-Tech to Develop New Nanopore DNA Sequencing System". Cambridge.

Organisations Organisation Base4 Innovation Ltd.
  Organisation 2 Hitachi High-Technologies Corporation (TSE: 8036)
  Group Hitachi (Group)
Products Product nanopore DNA sequencer
  Product 2 DNA sequencing technology
Index term Index term Base4–Hitachi: DNA sequencing system, 201307 collab development + manufacturing Nanopore DNA Sequencing System Hitachi High-Technologies
Persons Person Frayling, Cameron (Lightcast Discovery 201902– CEO + Co-Founder before Base4 201307 CEO + founder)
  Person 2 Koga, Yasukuni (Hitachi 201307 Head of Medical Systems Sales + Marketing Div of Hitachi High-Tech)

Base4 Innovation Ltd. ("Base4"), the privately-owned Cambridge-based DNA sequencing company, and Hitachi High-Technologies Corporation (TSE:8036, "Hitachi High-Tech"), a cutting-edge technology company developing and manufacturing scientific and medical systems, today announce that they have entered into a collaborative agreement to develop a long read-length, single-molecule, nanopore-based DNA sequencing system. The system will be based on innovative technology developed by Base4 and state-of-the-art instrumentation developed by Hitachi High-Tech.

The core DNA sequencing technology behind the system is based on the concept of passing a single strand of DNA through a nanometre scale pore and reading out the sequence directly as it does so. To achieve this, Base4 has developed a method of dramatically increasing the signal from this single molecule as it passes through the pore, using laser light enhanced by gold structures. The signal can be read from unlabelled DNA, requiring only minimal sample preparation.

Key features of this system will be its ability to directly read DNA modifications, such as methylation, which is very relevant to the genes associated with cancer, and its ability to achieve long read lengths. This will allow easy analysis of the genetic material, unlike the data from other sequencing systems which can be difficult to analyse and require substantial computing resources.

Commenting on the announcement of the collaboration with Hitachi High-Tech, Cameron Frayling, founder and CEO of Base4, said:

"Base4's objective is to develop a state-of-the-art instrument which makes it possible to answer new questions in the clinic and in the field of genomic research.

"For this nanopore sequencing system, Hitachi High-Tech is our preferred manufacturing partner. Development of this technology is expected to take place over three years, both in Cambridge and Hitachinaka-shi, Japan.

"Hitachi High-Tech is a highly experienced manufacturer of clinical and research systems for the life sciences and is a perfect long-term strategic partner for Base4. We are very excited by what the next few years might bring."

Yasukuni Koga, Head of Medical Systems Sales & Marketing Division, Science & Medical Systems Business Group of Hitachi High-Tech, added:

"Base4 is a young, exciting company and we are proud to work with them to develop and bring to market a new nanopore-based DNA sequencing system. We are excited to see what can be achieved by combining our high quality instrumentation and manufacturing capabilities with Base4's technology and drive towards innovation."

About Base4

Base4 Innovation Ltd. is a private company located in Cambridge, UK. Base4 is engaged in several development programs of technologies for high throughput DNA sequencing, diagnostics, and single-molecule analysis. For more information on Base4, please visit the company's website at

About Hitachi High-Tech

Hitachi High-Technologies Corporation, headquartered in Tokyo, Japan, is engaged in activities in a broad range of fields, including Electronic Device Systems, Fine Technology Systems, Science & Medical Systems, Industrial & IT Systems, and Advanced Industrial Products. The company's consolidated sales for FY 2012 were more than $6.1 billion. For further information, visit

Base4 contact:

Cameron Frayling, CEO Tel: +44 (0) 1223 358 652

Media contact:

Matthew Neal, M:Communications Tel: +44 (0) 207 920 2330

Record changed: 2019-06-09


Picture Kentro Design Corporate and Web Design Berlin 650x65px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BIO-Europe Spring 2020 Paris BEU2020 650x75

» top